Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

High Flow Nasal Cannula Versus Non-Invasive Ventilation in Exacerbations of Chronic Obstructive Pulmonary Disease (HiFOLD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03033251
Recruitment Status : Recruiting
First Posted : January 26, 2017
Last Update Posted : April 4, 2019
Sponsor:
Information provided by (Responsible Party):
St. Michael's Hospital, Toronto

Brief Summary:
Chronic obstructive lung disease is a disabling disease that affects people usually after several years of smoke tobacco exposure and affects millions of patients worldwide. The disease is marked by multiples episode of worsening, termed exacerbations necessitating frequent hospitalizations. During these exacerbations, patients present breathless, and in the most severe cases, are admitted to an Intensive Care Unit (ICU) for respiratory assistance. Currently, respiratory assistance is provided by a ventilator via a oronasal mask (referred to non-invasive ventilation, NIV), that helps patients to cope with their breathless. The mask is not always well tolerated and the ventilator sessions are delivered intermittently. In the past decade, a new technique that provides air-oxygen with high flow has been developed. This technique, called High Flow via Nasal Cannula (HFNC) can deliver from 21 to 100% heated and humidified air-oxygen at a high flow of gas via simple nasal cannula. Recent studies have shown that the technique is very efficient to treat patients presenting with acute respiratory failure who don't have any underlying chronic pulmonary disease. Whether the technique would be also efficient in patients with COLD presenting with severe exacerbations has not yet been demonstrated. Since HFNC does not require any mask, it is thought that the comfort of the patient would be much better in comparison to NIV and could potentially help to treat many patients with the disease. The objective of the present study is to study the physiological effect of HFNC as compared to NIV in patients with severe exacerbations of COPD and to show that it is non-inferior to NIV.

Condition or disease Intervention/treatment Phase
Exacerbation Copd Acute Respiratory Distress Device: Non Invasive Ventilation Device: High Flow Oxygen Cannula 50 Device: High Flow Oxygen Cannula 30 Not Applicable

Detailed Description:

Design: Prospective, observational, cross-over, clinical physiologic study of HFNC and NIV in patients with COPD and hypercapnic respiratory failure Intervention: Participants will be consecutively ventilated with the two devices, i.e., HFNC and NIV. HFNC 30 and 50 L/min will be applied in a random order (sealed, opaque envelope). HFNC will be set with a temperature at 37°C or 34°C if perceived as too warm. NIV settings will be adjusted based on the clinical assessment of the Respiratory Therapist as per standard practice and will not be modified during the test. In both groups, FiO2 will be adjusted to achieve a SpO2 of at least 92%.

Setting: The intervention will be applied in the Medical-Surgical ICU of St. Michael's Hospital.

Duration: Each device will be studied for 30 minutes. The entire study will take place over approximately 3 hours. There is no additional follow-up thereafter.

Procedures: The study will start first by recording patients under spontaneous breathing considered as a baseline (sequence #1). Under spontaneous breathing, patients will be receiving oxygen therapy as it is usually done between 2 NIV sessions. Then, the patient will have 20 -30 minutes to acclimatize to HFNC and select his/her preferred flow rate (sequence #2). NIV will be applied (sequence #3). The NIV settings will be adjusted based on the clinical assessment of the Respiratory Therapist and will not be modified throughout the study. Then, according to randomization order (sealed envelopes), patients will receive a flow corresponding to the preferred flow selected by the patient and a second flow, either HFNC 30 L/min or HFNC 50 L/min depending on the initial choice (sequences #4 and #5) (see flow diagram). FiO2 will be adjusted to achieve a SpO2 of 90 to 94%. Each condition will be studied for 30 minutes and will be separated by a 5-minute washout period during which patients will be receiving oxygen therapy. The measurements will be collected at baseline (under spontaneous breathing) and during the last five minutes of each condition. In case of clinical intolerance as considered by the attending physician, the study will stop. In case the patient is considered dependent of NIV by clinicians, we will still enroll the patient without doing baseline period after discussion with clinicians.

The pulse oximeter (SpO2) and transcutaneous CO2 monitor (SenTec Digital Monitoring System (SDMS)) will be continuously monitored throughout the study period. Exspiron device will be calibrated to measure minute ventilation. Four surface electrodes will be placed bilaterally to record each hemidiaphragm activity using a specific recording system (Acqknowledge software, Biopac Systems) A bedside ultrasound examination will be performed, using a SonoSite system (Fujifilm) equipped with a 10-15 MHz ultrasound linear probe. Diaphragm thickness will be measured both at end-inspiration and end-expiration. This technique will be applied at the end of each sequence (before ventilatory assist under conventional O2 therapy). In patients becoming rapidly intolerant to NIV disconnection, we will limit this "baseline" period under O2 to a minimum (5 minutes). The thickness and contraction of the intercostal muscles and abdominal muscles will also be assessed.

Interpretation of the ultrasound results to determine diaphragm and other muscle thickness will be read at a later time by an individual blinded to the intervention.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Intervention Model Description: Participants will receive 2 treatments (non invasive ventilation and high flow nasal cannula). The high flow nasal cannula will be applied with 2 flows (50 L/min and 30 L/min). The order of application of the 2 high flow sequences will be randomized (sealed opaque enveloppes).
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: High Flow Nasal Cannula Versus Non-Invasive Ventilation in Exacerbations of Chronic Obstructive Pulmonary Disease
Actual Study Start Date : September 2, 2018
Estimated Primary Completion Date : March 1, 2020
Estimated Study Completion Date : March 1, 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: COPD Lung Diseases

Arm Intervention/treatment
Active Comparator: Non invasive ventilation
Patients will receive non invasive ventilation with setting decided by the attending physician.
Device: Non Invasive Ventilation
Patients will receive non invasive ventilation as a standard of care.
Other Name: Standard of Care

Active Comparator: High Flow 50 L/min
High Flow Oxygen Cannula with a flow set at 50 L/min.
Device: High Flow Oxygen Cannula 50
Patients will receive High Flow Oxygen Cannula with a flow set at 50 L/min
Other Name: HFNO 50

Active Comparator: High Flow 30 L/min
High Flow Oxygen Cannula with a flow set at 30 L/min.
Device: High Flow Oxygen Cannula 30
Patients will receive High Flow Oxygen Cannula with a flow set at 30 L/min
Other Name: HFNO 30




Primary Outcome Measures :
  1. Change in work of breathing between NIV and HFNC [ Time Frame: 30 minutes ]

    The primary endpoint is to compare the decrease in work of breathing under HFNC to the decrease in work of breathing under NIV.

    The work of breathing will be assessed with diaphragm ultrasound (measurement of the diaphragm thickening fraction).



Secondary Outcome Measures :
  1. Change in Work of breathing between HFNC 50 and 30 L/min [ Time Frame: 30 minutes ]

    The secondary endpoints include comparison of the work of breathing under HFNC (50L/min vs 30 L/min).

    The work of breathing will be assessed with diaphragm ultrasound (measurement of the diaphragm thickening fraction).




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   40 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. COPD exacerbation with acute respiratory failure defined by

    • Respiratory acidosis (pH ≤7.35 and PaCO2 ≥45 mmHg);
    • Respiratory rate≥20 breaths/min;
    • Activation of accessory respiratory muscles;
  2. Undergone at least 1 hour of NIV since their admission
  3. English speaking
  4. Adult patient with age > 40 year old.

Exclusion Criteria:

  1. Severe respiratory acidosis defined by pH<7.25
  2. Decreased level of consciousness (Glasgow Coma Score Scale < 11)
  3. Urgent intubation required
  4. Pneumothorax with pleural drainage and persistent air leak
  5. Hemodynamic instability requiring vasopressors
  6. Uncooperative
  7. Patients with skin or chest wall or abdominal trauma (potentially worsened by placement of a surface sensor)
  8. Clinical judgement of the attending physician
  9. Body mass index > 35 kg/m2

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03033251


Contacts
Layout table for location contacts
Contact: Laurent Brochard, MD +1 416 864 5686 BrochardL@smh.ca
Contact: Martin Dres, MD +1 416 692 7420 DresM@smh.ca

Locations
Layout table for location information
Canada, Ontario
St. Michael's Hospital Recruiting
Toronto, Ontario, Canada, M5B 1W8
Contact: Laurent Brochard       brochardl@smh.ca   
Sponsors and Collaborators
St. Michael's Hospital, Toronto
Layout table for additonal information
Responsible Party: St. Michael's Hospital, Toronto
ClinicalTrials.gov Identifier: NCT03033251    
Other Study ID Numbers: REB# 16-389
First Posted: January 26, 2017    Key Record Dates
Last Update Posted: April 4, 2019
Last Verified: April 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by St. Michael's Hospital, Toronto:
COPD exacerbation
Work of breathing
Non invasive ventilation
High Flow Oxygen Cannula
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Diseases, Obstructive
Pulmonary Disease, Chronic Obstructive
Lung Diseases
Respiratory Tract Diseases